BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Drug Development

  Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022

  Intellia Therapeutics, Inc. today announced that it will be hosting two virtual investor events in February.

  February 17, 2022

   · 

  3 min read
• Business

  Avalo Therapeutics Announces Leadership Transition

  Avalo Therapeutics, Inc. announced today a leadership transition.

  February 17, 2022

   · 

  6 min read
• Business

  Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

  Kura Oncology, Inc. today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022.

  February 17, 2022

   · 

  2 min read
• Business

  Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2021.

  February 17, 2022

   · 

  19 min read
• Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study

  Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study Evaluating the Renuvion ® Dermal Handpiece Using Apyx’s Helium Plasma Technology for Dermal Resurfacing Procedures.

  February 17, 2022

   · 

  7 min read
• Drug Development

  Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

  Maze Therapeutics today announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.

  February 17, 2022

   · 

  2 min read
• Business

  Oncology Pharma Expands on Feasibility Studies and Data

  Oncology Pharma Inc. wants to expand on a previously announced press release that included results of formulations and data on licensed technology with NanoSmart Pharmaceuticals.

  February 17, 2022

   · 

  7 min read
• Business

  Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

  Alimera Sciences, Inc. announces today that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, prior to the market open.

  February 17, 2022

   · 

  1 min read
• Business

  OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financial markets on Thursday, February 24, 2022.

  February 17, 2022

   · 

  1 min read
• Policy

  BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia

  BeiGene announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy.

  February 17, 2022

   · 

  8 min read